multiple myeloma

Conference Coverage

Real-world Outcomes of ASCT in Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma

12/10/2022

Julie Cote, MD, and colleagues discuss real-world outcomes of patients treated with autologous stem cell transplant as part of their initial multiple myeloma therapy during their presentation at the 64th ASH Annual Meeting and Exposition.

Julie Cote, MD, and colleagues...

12/10/2022

Journal of Clinical Pathways

Videos

Dr Fonseca Highlights Phase 2 GRIFFIN Study Results for Newly Diagnosed MM

12/13/2021

Rafael Fonseca, MD, Mayo Clinic, discusses new results from the Phase 2 GRIFFIN study of daratumumab, as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the 2021 ASH Annual Meeting.

Rafael Fonseca, MD, Mayo Clinic,...

12/13/2021

Oncology

NCCN Updates Clinical Practice Guideline for Multiple Myeloma

03/15/2021

Janelle Bradley ;

The National Comprehensive Cancer Network released an update to its clinical practice guideline for multiple myeloma.

The National Comprehensive...

03/15/2021

Journal of Clinical Pathways

News

DRd Improves PROs Compared With Rd for Newly Diagnosed MM

02/01/2021

Journal of Clinical Pathways

FDA Alerts

FDA Approves Selinexor in Combination With Bortezomib and Dexamethasone for MM

12/18/2020

Journal of Clinical Pathways

News

Risk Score to Predict Early Infection in Patients With Multiple Myeloma

06/26/2020

A post-hoc analysis presented at the European Hematology Association (EHA) Annual Meeting (June 11-21, 2020) led to a new risk prediction score for early severe infection in patients with multiple myeloma. Many...

A...

06/26/2020

Journal of Clinical Pathways

News

Isatuximab Combination Effective in Myeloma and Soft-Tissue Plasmacytomas

06/22/2020

Isatuximab plus pomalidomide and dexamethasone (Isa-Pd) significantly prolongs progression-free survival (PFS) and improves overall response rate (ORR) compared with pomalidomide plus dexamethasone alone (Pd) in...

...

06/22/2020

Journal of Clinical Pathways

News

HRQoL of Patients With Heavily Pretreated or Renally Impaired Multiple Myeloma

06/18/2020

Isatuximab in combination with pomalidomide and dexamethasone may provide an effective treatment option in relapsed or refractory multiple myeloma, including difficult-to-treat subgroups of these patients, and may...

...

06/18/2020

Journal of Clinical Pathways

Feature

Multidisciplinary Management of Multiple Myeloma in Older Adults

08/17/2017

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Shelby Knowles , MD;

Sidrah Khan , MD;

Nader Tavakoli , MD, CMD, FAAFP;

Abstract: Multiple myeloma (MM) is a progressive and fatal disease, primarily affecting men aged 66 years or older. Because MM is primarily a disease of the elderly, it is incumbent on geriatricians and primary care...

...

08/17/2017

Journal of Clinical Pathways

Author Insights

Cost-Effective Alternative Identified for Autologous Stem Cell Mobilization in Multiple Myeloma

08/14/2017

Pavan Bhamidipati , MBBS, MD;

In a randomized, open-label study, we discovered that tbo-filgrastim (Granix) can be used in the place of filgrastim (Neupogen) for autologous stem cell mobilization for multiple myeloma and non-Hodgkin’s lymphoma...

In a...

08/14/2017

Journal of Clinical Pathways